Summary & Overview
HCPCS J1921: Labetalol Hydrochloride (Hikma) Injection, 5 mg
HCPCS Level II code J1921 denotes a 5 mg injectable dose of labetalol hydrochloride (Hikma), specified as not therapeutically equivalent to J1920. This designation matters nationally because it distinguishes manufacturer-specific products for parenteral antihypertensive therapy, which can affect coding, billing, procurement, and payer coverage decisions across hospital and clinic settings. Accurate coding ensures appropriate product identification for administration, inventory, and reimbursement processes.
Key payers covered in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find an overview of clinical context for parenteral labetalol use, typical sites of service where the code applies, and the implications of a non-equivalent product designation. The publication outlines benchmark considerations for payers, common modifier usage patterns (list provided separately), and policy-related points that affect coverage and claims processing.
This summary provides practical information for billing staff, revenue cycle managers, and clinical teams who must reconcile administered products with billed codes, and for policy analysts monitoring payer guidance on branded versus equivalent injectable medications. Data not available in the input is noted where applicable.
Billing Code Overview
HCPCS Level II code J1921 describes an injection of labetalol hydrochloride (Hikma), 5 mg, noted as not therapeutically equivalent to J1920. This code represents a specific branded or manufacturer-specified formulation of labetalol used for parenteral administration.
Service type: Injectable antihypertensive medication administration
Typical site of service: Hospital inpatient or outpatient infusion/administration setting, emergency department, or clinic where parenteral antihypertensive therapy is delivered
Data not available in the input.
Clinical & Coding Specifications
Clinical Context
A typical patient is a hypertensive adult presenting to an emergency department, labor and delivery unit, or inpatient ward with acute severe hypertension or hypertensive emergency requiring rapid blood-pressure control. Labetalol hydrochloride J1921 is administered intravenously in 5 mg units (billing per 5 mg) when rapid titratable beta- and alpha-blockade is desired, for example in acute systolic blood pressure ≥180 mm Hg or diastolic ≥120 mm Hg with end-organ risk, or in severe hypertension during pregnancy (e.g., preeclampsia with severe features).
In the clinical workflow, the patient is triaged and monitored with continuous blood-pressure and cardiac monitoring, IV access is secured, baseline vital signs and relevant labs are obtained, and a healthcare provider (emergency physician, hospitalist, or obstetrician) orders IV labetalol. Pharmacy prepares/vials the medication; nursing administers the IV bolus or infusion per protocol; dose is documented in the medication administration record and the medication is billed using J1921 in 5 mg increments. Post-administration monitoring evaluates blood-pressure response and adverse effects (bradycardia, bronchospasm). Typical sites of service include Emergency Department, Inpatient Hospital (acute care), and Labor & Delivery/Obstetric unit. Common patient scenarios include hypertensive emergency, severe symptomatic hypertension, or acute management of blood pressure in pregnancy.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|